User profiles for JULIE LEMIEUX

Julie Lemieux

Centre de recherche du CHU de Québec-Université Laval
Verified email at crchudequebec.ulaval.ca
Cited by 3998

Chemotherapy‐induced alopecia and effects on quality of life among women with breast cancer: a literature review

J Lemieux, E Maunsell… - Psycho‐Oncology: Journal …, 2008 - Wiley Online Library
Background: Alopecia is a common side effect of chemotherapies used in the treatment of
breast cancer. The aim of this review is to describe the effects of alopecia on quality of life (…

Strain-guided management of potentially cardiotoxic cancer therapy

…, E Somerset, K Negishi, M Penicka, J Lemieux… - Journal of the American …, 2021 - jacc.org
Background In patients at risk of cancer therapy-related cardiac dysfunction (CTRCD), initiation
of cardioprotective therapy (CPT) is constrained by the low sensitivity of ejection fraction (…

Effect of metformin vs placebo on invasive disease–free survival in patients with breast cancer: the MA. 32 randomized clinical trial

…, BE Chen, KA Gelmon, TJ Whelan, M Ennis, J Lemieux… - Jama, 2022 - jamanetwork.com
Importance Metformin, a biguanide commonly used to treat type 2 diabetes, has been
associated with potential beneficial effects across breast cancer subtypes in observational and …

Canadian Cardiovascular Society guidelines for evaluation and management of cardiovascular complications of cancer therapy

…, MK Davis, DS Jassal, C Johnson, J Lemieux… - Canadian Journal of …, 2016 - Elsevier
Modern treatment strategies have led to improvements in cancer survival, however, these
gains might be offset by the potential negative effect of cancer therapy on cardiovascular health…

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

…, F Fitzal, T Traina, A Chan, HS Rugo, J Lemieux… - The lancet …, 2021 - thelancet.com
Background Palbociclib added to endocrine therapy improves progression-free survival in
hormone-receptor-positive, HER2-negative, metastatic breast cancer. The PALLAS trial aimed …

[PDF][PDF] Lapatinib or trastuzumab plus taxane therapy for human epidermal growth factor receptor 2-positive advanced breast cancer: final results of NCIC CTG MA. 31

…, A Di Leo, M Martin, LS Schwartzberg, J Lemieux… - J Clin …, 2015 - researchgate.net
… Schwartzberg, Julie Lemieux, Samuel Aparicio, Lois E. Shepherd, Susan Dent, Susan L.
Ellard, Katia Tonkin, Kathleen I. … Boyle, Bella Kaufman, Julie Lemieux, Samuel Aparicio …

Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents

PJ Goodwin, V Stambolic, J Lemieux, BE Chen… - Breast cancer research …, 2011 - Springer
Metformin, an inexpensive oral agent commonly used to treat type 2 diabetes, has been
garnering increasing attention as a potential anti-cancer agent. Preclinical, epidemiologic, and …

Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001–2009)

J Lemieux, PJ Goodwin, LJ Bordeleau… - Journal of the …, 2011 - academic.oup.com
Background Quality-of-life (QOL) measurement is often incorporated into randomized
clinical trials in breast cancer. The objectives of this systematic review were to assess the …

Effect of metformin vs placebo on weight and metabolic factors in NCIC CTG MA. 32

…, IA Mayer, TJ Hobday, J Lemieux… - Journal of the …, 2015 - academic.oup.com
Background: Metformin may improve metabolic factors (insulin, glucose, leptin, highly sensitive
C-reactive protein [hs-CRP]) associated with poor breast cancer outcomes. The NCIC …

[HTML][HTML] Smoking at time of diagnosis and breast cancer-specific survival: new findings and systematic review with meta-analysis

S Bérubé, J Lemieux, L Moore, E Maunsell… - Breast Cancer …, 2014 - Springer
Introduction In women with breast cancer who smoke, it is unclear whether smoking could
impair their survival from the disease. Methods We examined the relation of smoking at …